GlassScriptPhysician profile
Cherechi C Ogwo
NPI 1720321060
$3,653.41
in general payments reported to CMS, 2019-2025
25 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.66 · 2020: $199 · 2021: $716 · 2022: $816 · 2023: $482 · 2024: $657 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.99 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $733.29 | 2020-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $505.82 | 2020-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $372.91 | 2021-2025 | Korlym |
| Cequr Corporation | $308.84 | 2023-2025 | Cequr Simplicity |
| Insulet Corporation | $276.25 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.53 | 2021-2025 | Jardiance |
| Abbott Laboratories | $250.96 | 2021-2024 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $155.86 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $142.67 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.13 | 2022-2024 | |
| Ibsa Pharma INC. | $72.27 | 2020-2023 | Tirosint, Licart |
| Sequel Med Tech, LLC | $72.25 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $63.80 | 2021-2025 | Gvoke Hypopen |
| Abbvie INC. | $62.30 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $59.89 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $43.12 | 2025 | |
| Pfizer INC. | $23.77 | 2019 | |
| Medtronic Minimed, INC. | $22.38 | 2020 | |
| Kyowa Kirin, INC. | $18.83 | 2023 | Crysvita |
| Amgen INC. | $15.98 | 2025 | Tepezza |
| Lifescan, INC. | $15.86 | 2022 | |
| Merck Sharp & Dohme LLC | $14.38 | 2021 | |
| Evoke Pharma, INC. | $13.39 | 2022 | |
| Dexcom, INC. | $13.16 | 2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherechi Ogwo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.